Early-Onset Neonatal Sepsis: A Comprehensive Clinical Review

Recent Trends

Clinicians have increasingly shifted toward risk-stratified management strategies for suspected early-onset sepsis (EOS) in neonates. Several large observational studies published over the past several years highlight a decline in empiric antibiotic use in asymptomatic infants born at or near term, driven by refined screening algorithms and biomarkers such as serial physical examination and C-reactive protein trends.

• Adoption of multivariate risk calculators (e.g., the Kaiser Permanente neonatal sepsis calculator) has been reported in many delivery centers, associated with fewer newborns receiving prolonged antibiotic courses without an observed increase in missed infections.
• Culture-independent molecular diagnostics (e.g., multiplex PCR panels) have entered limited clinical use, though their sensitivity for low–inoculum bacteremia remains under evaluation.
• Regional variation persists: some centers still use complete blood count panels with thresholds drawn from older literature, leading to higher empiric treatment rates.

Background

Early-onset neonatal sepsis is defined as a bloodstream infection occurring within the first 72 hours of life, most often acquired vertically from the maternal genital tract. Group B Streptococcus (GBS) and Escherichia coli account for the majority of cases. Universal maternal GBS screening and intrapartum antibiotic prophylaxis, introduced in the late 1990s, substantially reduced the incidence of GBS disease, but E. coli has become relatively more prominent, especially in preterm and very low birth weight infants.

Diagnosis remains challenging because signs are nonspecific (respiratory distress, temperature instability, poor feeding) and blood cultures—the gold standard—can be falsely negative if the volume is insufficient or antibiotics are given earlier. This diagnostic uncertainty has led to ongoing debates about when to initiate therapy and how long to continue it in clinically stable infants with negative cultures.

User Concerns

Parents and clinicians alike worry about both the risk of a missed infection and the consequences of unnecessary antibiotics. Key concerns include:

• Uncertainty around risk thresholds: What incidence of culture-proven sepsis justifies starting antibiotics? A rate of 0.5–1 per 1,000 term live births is common, making decision-making highly sensitive to local epidemiology.
• Duration of therapy: Standard practice for culture-negative, clinically well infants remains 36–48 hours of antibiotics, but some clinicians advocate shorter courses for those with low clinical suspicion.
• Impact of maternal antibiotics: Intrapartum prophylaxis can sterilize neonatal blood cultures, leaving clinicians without confirmation while the clinical picture may still suggest infection.
• Long-term microbiome effects: Even short courses of broad-spectrum antibiotics in the first days of life are associated with alterations in gut microbiota and increased risk of later allergic and metabolic conditions.

Likely Impact

Ongoing refinements in risk assessment and biomarker use are expected to further reduce unnecessary antibiotic exposure without raising rates of missed sepsis. However, the impact will vary by setting.

• In well-resourced level III nurseries, integration of procalcitonin and serial clinical scores may allow many asymptomatic infants to avoid any antibiotic treatment, shortening hospital stays by 1–2 days on average.
• In settings with limited laboratory capacity, reliance on clinical decision rules alone may increase initial overtreatment but can decrease culture-negative duration if combined with strict stopping criteria.
• For preterm infants (especially <32 weeks), the risk–benefit calculus differs: higher sepsis incidence (5–15%) and greater vulnerability mean empiric coverage with ampicillin and an aminoglycoside is likely to remain standard, though de-escalation within 48 hours for negative cultures may become more routine.
• The use of rapid molecular tests may shorten time to pathogen identification by 12–24 hours, enabling earlier targeted therapy and shorter empiric windows, though cost and availability remain barriers.

What to Watch Next

Several developments are likely to shape the clinical landscape in the near term:

• Prospective validation of proposed universal screening algorithms that combine maternal risk factors with neonatal clinical status and point-of-care biomarkers.
• Publication of multicenter implementation studies comparing the outcomes of centers using a risk calculator versus those using local laboratory thresholds.
• Emergence of antibiotic stewardship bundles specifically designed for the neonatal intensive care unit, including mandatory stop orders after 48 hours for culture-negative infants.
• Further evaluation of targeted rapid PCR panels covering both GBS and common Gram-negative pathogens, particularly in preterm populations where E. coli predominates.
• Guideline updates from national bodies expected to incorporate newer evidence on the safety of observation alone in low-risk term infants, potentially narrowing the definition of “clinical chorioamnionitis” that triggers empiric antibiotics.